Alx Oncology Holdings (ALXO) Operating Expenses (2019 - 2026)

Alx Oncology Holdings (ALXO) has 8 years of Operating Expenses data on file, last reported at $19.0 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 40.4% year-over-year to $19.0 million; the trailing twelve-month figure through Mar 2026 stood at $91.2 million (down 33.22% YoY), and the FY2025 full-year result was $104.0 million, down 26.99% from the prior year.
• Operating Expenses declined to $19.0 million in Q1 2026, from $23.0 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $53.3 million in Q3 2023 to a low of $19.0 million in Q1 2026.
• A 5-year average of $33.1 million and a median of $32.2 million in 2022 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses soared 107.31% in 2022 and plunged 40.4% in 2026, its largest moves.
• Tracing ALXO's Operating Expenses over 5 years: stood at $32.2 million in 2022, then surged by 49.05% to $48.0 million in 2023, then tumbled by 36.25% to $30.6 million in 2024, then decreased by 24.8% to $23.0 million in 2025, then slipped by 17.61% to $19.0 million in 2026.
• Business Quant data shows ALXO's Operating Expenses at $19.0 million in Q1 2026, $23.0 million in Q4 2025, and $22.5 million in Q3 2025.